Literature DB >> 17046376

Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives.

David F Archer1.   

Abstract

As many as 80% of reproductive-aged women experience physical changes associated with menstruation, and 20% to 40% experience menstrual-cycle-related symptoms. Decades of research in women with menstrual disorders, such as dysmenorrhea and menorrhagia, have shown that continuous use of oral contraceptives (OCs), without the hormone-free interval, is a safe and effective method to relieve these symptoms and ultimately induce amenorrhea in many women. If given the opportunity, a majority of women would opt for extended-cycle or continuous regimens, and numerous clinical trials have shown that continuous OC regimens induce amenorrhea in 80% to 100% of women by 10 to 12 months of use. For women who do not wish to become pregnant, a continuous OC regimen should be an available option.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17046376     DOI: 10.1016/j.contraception.2006.06.003

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  9 in total

Review 1.  Contraception and abortion.

Authors:  Sam Rowlands
Journal:  J R Soc Med       Date:  2007-10       Impact factor: 5.344

Review 2.  The Sexual Acceptability of Contraception: Reviewing the Literature and Building a New Concept.

Authors:  Jenny A Higgins; Nicole K Smith
Journal:  J Sex Res       Date:  2016-03-08

Review 3.  Prevention and treatment of menstrual migraine.

Authors:  E Anne MacGregor
Journal:  Drugs       Date:  2010-10-01       Impact factor: 9.546

4.  Safety data and beneficial effects of the combined oral contraceptive ethinylestradiol 0.03 mg/chlormadinone acetate 2 mg (Belara®): a 13-cycle, observational study in routine clinical practice.

Authors:  Daphnee S Pushparajah; Petra Röhm; Kornelia Höschen; Dagmar Albers; Christina Nowack
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 5.  Hormonal therapies for menstrual migraine.

Authors:  Anne H Calhoun; Susan Hutchinson
Journal:  Curr Pain Headache Rep       Date:  2009-10

6.  The lowest-dose, extended-cycle combined oral contraceptive pill with continuous ethinyl estradiol in the United States: a review of the literature on ethinyl estradiol 20 μg/levonorgestrel 100 μg + ethinyl estradiol 10 μg.

Authors:  Sheila Krishnan; Jessica Kiley
Journal:  Int J Womens Health       Date:  2010-08-10

Review 7.  Heavy menstrual bleeding diagnosis and medical management.

Authors:  Intira Sriprasert; Tarita Pakrashi; Thomas Kimble; David F Archer
Journal:  Contracept Reprod Med       Date:  2017-07-24

Review 8.  Acupuncture for Primary Dysmenorrhea: An Overview of Systematic Reviews.

Authors:  Furong Zhang; Mingsheng Sun; Shanshan Han; Xiaoyu Shen; Yanan Luo; Dongling Zhong; Xiujuan Zhou; Fanrong Liang; Rongjiang Jin
Journal:  Evid Based Complement Alternat Med       Date:  2018-11-21       Impact factor: 2.629

Review 9.  Extended regimen combined oral contraception: A review of evolving concepts and acceptance by women and clinicians.

Authors:  Rossella E Nappi; Andrew M Kaunitz; Johannes Bitzer
Journal:  Eur J Contracept Reprod Health Care       Date:  2015-11-17       Impact factor: 1.848

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.